TrialPath
Multiple sclerosis · Miami

Multiple sclerosis clinical trials in Miami

7 recruiting multiple sclerosis studies within range of Miami. Click any trial for full eligibility criteria and contact info.

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Recruiting

The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

PhasePhase 3
TypeInterventional
Age40 Years – 70 Years
WhereScottsdale, Arizona, United States + 130 more
SponsorNovartis Pharmaceuticals
▾Tap for details
Apply

TSC Biosample Repository and Natural History Database

NCT05676099 · Tuberous Sclerosis, Lymphangioleiomyomatosis
Recruiting

The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.

Phase—
TypeObservational
AgeAny
WhereBirmingham, Alabama, United States + 25 more
SponsorNational Tuberous Sclerosis Association
▾Tap for details
Apply

Longitudinal Cognitive Assessment by BoCA

NCT04114994 · Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia
Recruiting

The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.

Phase—
TypeObservational
Age50 Years
WhereMiami, Florida, United States
SponsorAlzheimer's Light LLC
▾Tap for details
Apply

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Recruiting

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

PhasePhase 3
TypeInterventional
Age18 Years – 65 Years
WhereBirmingham, Alabama, United States + 295 more
SponsorNovartis Pharmaceuticals
▾Tap for details
Apply

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Recruiting

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 112 more
SponsorTG Therapeutics, Inc.
▾Tap for details
Apply

Clinical Applications of Advanced Ophthalmic Imaging

NCT03135327 · Multiple Sclerosis, Dry Eye Syndromes, Diabetic Retinopathy
Recruiting

The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls. There are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.

PhaseNA
TypeInterventional
Age18 Years – 99 Years
WhereMiami, Florida, United States
SponsorUniversity of Miami
▾Tap for details
Apply

A Study of AZD0120 in Autoimmune Diseases

NCT07295847 · Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Recruiting

This trial is a Phase 1b/2, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 75 Years
WhereTucson, Arizona, United States + 26 more
SponsorAstraZeneca
▾Tap for details
Apply